Inspired by Patients, Every day.

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

Inspired by Patients, Every day.

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

XPO1 Inhibition & SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells.

XPO1 Inhibition & SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells.

Karyopharm Pipeline

With four unique drug candidates in clinical development, Karyopharm is developing medicines that target patients with cancer in both hematologic and solid tumors.

Karyopharm Pipeline

With four unique drug candidates in clinical development, Karyopharm is developing medicines that target patients with cancer in both hematologic and solid tumors.

Our Commitment to Patients

At Karyopharm, patients are at the core of everything we do. They inspire us, keep us motivated, and are critical in our pursuit of developing important new medicines.

Our Commitment to Patients

At Karyopharm, patients are at the core of everything we do. They inspire us, keep us motivated, and are critical in our pursuit of developing important new medicines.

Karyopharm Clinical Trials

Karyopharm has ongoing clinical trials for our lead drug candidate and next-generation programs in earlier lines of treatment, in combination trials, and in a variety of tumor types across both hematologic and solid tumors.

Karyopharm Clinical Trials

Karyopharm has ongoing clinical trials for our lead drug candidate and next-generation programs in earlier lines of treatment, in combination trials, and in a variety of tumor types across both hematologic and solid tumors.

Recent Medical Conferences

ASCO 2022: Karyopharm Presentations and Posters

June 3 -7, Chicago, IL

Join The Karyopharm Team

“If you work hard and show the initiative, you are trusted to pursue your professional curiosities, and can be rewarded with work experiences usually reserved for more senior employees. I’ve been well-versed with new skills, and I got to be part of an initiative that might otherwise be considered above my pay grade at another organization.  Karyopharm accomplishes so much that the excitement is infectious, and I have no doubt I will have a fruitful career here”

Alan Finance Senior Manager – R&D

“Joining Karyopharm gave me the great learning opportunity to become an oncology statistician. I have experienced accelerated career development and plenty of opportunities to motivate myself and expand my comfort zones and skill set. It is extremely rewarding to know that my work is benefiting patients.”

Lingling AVP, Biostatistics
Alan